MoonLake Immunotherapeutics Class A Ordinary Shares
MLTXMoonLake Immunotherapeutics is a biotechnology company focused on developing innovative immuno-oncology therapies. The company specializes in creating treatments that harness the body's immune system to target and combat cancer, with an emphasis on complement pathway modulation. Its pipeline includes a variety of investigational drugs aimed at improving outcomes for patients with difficult-to-treat cancers.
Company News
The Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly making false and misleading statements about its drug candidate sonelokimab, which led to a significant stock price drop after disappointing Phase 3 trial results.
The Schall Law Firm is pursuing a securities fraud lawsuit against MoonLake Immunotherapeutics, alleging the company made false claims about its drug candidate sonelokimab and misled investors about its treatment superiority, resulting in a 90% stock value loss.
A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging securities fraud related to misrepresentations about their drug candidate sonelokimab, which led to significant stock value loss.
Rosen Law Firm is pursuing a securities class action lawsuit against MoonLake Immunotherapeutics, alleging false and misleading statements about their Nanobody technology and its clinical benefits during the period of March 10, 2024 to September 29, 2025.
Hagens Berman is pursuing a securities class action lawsuit against MoonLake Immunotherapeutics after its stock plummeted 90% following disappointing Phase 3 trial results for its lead drug sonelokimab, alleging the company made misleading claims about its Nanobody technology's clinical efficacy.
